SCHEMBL12823485

SCHEMBL12823485

CCCC(O)c1ccc(-c2ccc(OC(=O)c3ccc(-c4ccc(O)cc4F)cc3)c(F)c2F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ RARB P10826 1/20 0.37
▸ ESR1 P03372 5/20 0.35
▸ PTGS2 P35354 2/20 0.34
▸ ABCB1 P08183 1/20 0.34
▸ ADRB1 P08588 1/20 0.34
▸ ADRB3 P13945 1/20 0.34
▸ AKR1C3 P42330 1/20 0.34
▸ AKR1C2 P52895 1/20 0.34
▸ HCAR2 Q8TDS4 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ TAS1R3 Q7RTX0 1/20 0.33
▸ TAS1R1 Q7RTX1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12823717 0.94 TAS1R3 (0.36) APPCYP2C19CYP3A4CYP2C9RARB
SCHEMBL12823475 0.88 EGFR (0.32) RARBADRB1TAS1R3TAS1R1MAPT
SCHEMBL12823697 0.88 EGFR (0.32) RARBADRB1TAS1R3TAS1R1MAPT
SCHEMBL12822961 0.87 KDM4E (0.39) APPCYP2C19CYP3A4CYP2C9RARB
SCHEMBL12822091 0.87 FAAH (0.36) PTGS2ADRB1ADRB3TAS1R3TAS1R1
SCHEMBL12821297 0.85 FAAH (0.42) PTGS2ADRB1ADRB3TAS1R3TAS1R1
SCHEMBL12823210 0.85 ABCB1 (0.38) APPCYP2C19CYP3A4CYP2C9ESR1
SCHEMBL12823198 0.85 APP (0.34) APPCYP2C19RARBPTGS2ADRB1
SCHEMBL12823722 0.83 MAPT (0.40) PTGS2TAS1R3TAS1R1MAPT
SCHEMBL12717881 0.82 S1PR1 (0.37) APPCYP2C19RARBPTGS2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110090450-A1 FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2011-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110090450-A1 FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE LEF1, LAS1L, EFHD2 APP 2200/4885CYP2C19 2333/4885CYP3A4 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback